PDCD1 and cholangiocarcinoma: Among advanced CCA patients with MSI-H/dMMR treated with the PD-1 inhibitor pembrolizumab in the Keynote-158 study could achieve a 40.9% objective response rate (ORR) [23], indicating that patients with MSI-H are highly sensitive to PD-1 inhibitors.